Holly Liptak; Manjot K. Gill, MD , 2025-04-21 20:00:00
April 21, 2025
1 min watch
In this expert perspective, Manjot K. Gill, MD, discusses the potential FDA approval in 2025 of aflibercept 8 mg for the treatment of retinal vein occlusion.
Gill, vice chair of clinical performance and ophthalmology professor at Northwestern Feinberg School of Medicine, said the results of the QUASAR study of aflibercept 8 mg were positive regarding noninferiority and best corrected visual acuity gains relative to aflibercept 2 mg.
“The addition of 8 mg, which is four times the molar concentration of the currently available 2 mg, has the potential for enhanced efficacy but also for enhanced durability, allowing our patients to be extended for longer treatment intervals with fewer injections,” Gill said. “So that certainly is a very exciting addition to our treatment armamentarium for managing our patients with retinal vein occlusion.”
Sources/Disclosures
Collapse
Source:
Healio interviews
Disclosures:
Gill reports speaking, consulting or advising for Genentech and Regeneron.
